Intravesical hyaluronic acid (HA) with BCG |
Phase 2, randomized, pilot study to examine effect of HA in reducing BCG induced local cytotoxicity |
NCT02207608 |
Bladder urothelial cell carcinoma |
(12) |
Tislelizumab in Combination with BCG |
Phase 2, open-label, single-arm, single center trial to evaluate safety and effectiveness of Tislelizumab along with BCG (TACBIN-01) |
NCT04922047 |
High risk urinary bladder cancers |
(13) |
Vitamin D supplementation in adjunct to BCG immunization in infants |
Randomized, double masked, interventional study to evaluate impact of vitamin D supplement in infants prior to BCG vaccination |
NCT01288950 |
Tuberculosis |
(14) |
Vitamin A with BCG Vaccine |
Phase 4, randomized, double-masked intervention to evaluate the utility of high-dose vitamin A supplementation in infants along with BCG vaccine at birth |
NCT00168597 |
Mortality and morbidity in infants |
(15) |
Monoclonal Antibody A1G4 and BCG |
Phase 1 intervention to evaluate the efficacy of monoclonal antibody A1G4 along with BCG in cancer patients |
NCT00003023 |
* Neuroblastoma, Sarcoma |
(16) |